Cargando…

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

OBJECTIVE: Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer were retrospectively analysed to investigate the effects of primary tumour location and early tumour shrinkage on outcomes. METHODS: Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Köhne, Claus-Henning, Karthaus, Meinolf, Mineur, Laurent, Thaler, Josef, Van den Eynde, Marc, Gallego, Javier, Koukakis, Reija, Berkhout, Marloes, Hofheinz, Ralf-Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738356/ https://www.ncbi.nlm.nih.gov/pubmed/31300973 http://dx.doi.org/10.1007/s40268-019-0278-8

Ejemplares similares

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
por: Karthaus, Meinolf, et al.
Publicado: (2016)

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
por: Taieb, Julien, et al.
Publicado: (2017)

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
por: Thaler, Josef, et al.
Publicado: (2012)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
por: Peeters, Marc, et al.
Publicado: (2018)

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
por: Koukakis, Reija, et al.
Publicado: (2016)

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
por: Aparicio, Jorge, et al.
Publicado: (2022)

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC
por: Hebart, Holger, et al.
Publicado: (2019)

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
por: Siena, Salvatore, et al.
Publicado: (2016)

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study
por: Piringer, Gudrun, et al.
Publicado: (2023)

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
por: Rivera, Fernando, et al.
Publicado: (2017)

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
por: Modest, Dominik Paul, et al.
Publicado: (2019)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
por: Liao, Michael Z, et al.
Publicado: (2020)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
por: Shitara, Kohei, et al.
Publicado: (2016)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
por: Liao, Michael Z, et al.
Publicado: (2020)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
por: Liu, Yuguo, et al.
Publicado: (2015)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
por: Han van Krieken, J., et al.
Publicado: (2017)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
por: Sagawa, Tamotsu, et al.
Publicado: (2020)

Paraneoplastic Cushing Syndrome in Gastrointestinal Neuroendocrine Tumour
por: Mineur, Laurent, et al.
Publicado: (2021)

Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer
por: Lyskjær, Iben, et al.
Publicado: (2019)

K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location.
por: Breivik, J., et al.
Publicado: (1994)

Durable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
por: Kim, Esther, et al.
Publicado: (2019)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
por: Hofheinz, Ralf-Dieter, et al.
Publicado: (2022)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
por: Battaglin, Francesca, et al.
Publicado: (2019)

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
por: Liao, Michael Z., et al.
Publicado: (2021)

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma
por: Peeters, Marc, et al.
Publicado: (2018)

Mutations of K-ras oncogene in human adrenal tumours in Taiwan.
por: Lin, S. R., et al.
Publicado: (1998)

Resistance of R-Ras knockout mice to skin tumour induction
por: May, Ulrike, et al.
Publicado: (2015)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
por: Fischer, Laura E., et al.
Publicado: (2022)

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
por: Boeckx, N., et al.
Publicado: (2017)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bkq1t0hdft4jb1vkpu8453mdjf